Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ASC47, a muscle-preserving weight loss drug candidate, in combination with semaglutide, demonstrated up to 56.2% greater relative reduction ...
Back in my 20s, I was a regular “party smoker”, sparking up on a night out with friends, or heading outside for a cheeky fag during a raucous dinner party. Smoking was part of the ritual of going out, ...
LOWCOUNTRY, S.C. (WCIV) — Dr. David Geier joined Good morning Charleston Wednesday to break down a new study and talk about some of the myths surrounding a persons BMI and what measurement tool might ...
- Ultra-long-acting subcutaneous (SQ) depot formulation of ASC47 demonstrated a lower rebound effect after treatment discontinuation compared to the semaglutide monotherapy group, supporting the ...
-The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback